FrancophonIA/ELRC3.0 huggingface dataset:
English: Chronic hepatitis C and HIV co-infection
Slovenian: Kronični hepatitis C in sočasna okužba s HIV
English: The use of Pegasys and ribavirin combination therapy in CHC patients who failed prior treatment has not been adequately studied in patients who discontinued prior therapy for haematological adverse reactions.
Slovenian: Uporaba kombinacije zdravila Pegasys in ribavirina pri bolnikih s CHC, pri katerih prejšnje zdravljenje ni bilo uspešno, ni zadostno raziskana pri tistih, ki so prejšnje zdravljenje prekinili zaradi hematoloških neželenih učinkov.
English: It is recommended that patients who have pre-existing cardiac abnormalities have an electrocardiogram prior to initiation of Pegasys therapy.
Slovenian: Priporočljivo je, da pri bolnikih s predhodnimi motnjami v delovanju srca pred začetkom zdravljenja z zdravilom Pegasys naredimo elektrokardiogram.
English: Hold the pre-filled pen firmly with one hand and pull off the protective cap with the other hand.
Slovenian: Z eno roko trdno primite napolnjeni injekcijski peresnik, z drugo pa povlecite zaščitni pokrovček.
English: All patients received ribavirin (1000 or 1200 mg/day) in combination with Pegasys.
Slovenian: Vsi bolniki so v kombinaciji z zdravilom Pegasys prejeli ribavirin (1000 ali 1200 mg/dan).
English: The use of Pegasys in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).
Slovenian: Uporaba zdravila Pegasys pri otrocih in mladostnikih s hudimi psihičnimi stanji ali hudimi psihičnimi stanji v anamnezi je kontraindicirana (glejte poglavje 4.3).
English: You will find the expiration date on the box as well as on the label of the pre-filled pen itself.
Slovenian: Rok uporabnosti najdete na škatli in na nalepki napolnjenega injekcijskega peresnika.
English: Ribavirin should be discontinued if either of the following applies: (1) a patient without significant cardiovascular disease experiences a fall in haemoglobin confirmed to < 8.5 g/dl; (2) a patient with stable cardiovascular disease maintains a haemoglobin value < 12 g/dl despite 4 weeks on a reduced dose.
Slovenian: Ribavirin prenehamo dajati v naslednjih primerih: (1) pri bolniku brez pomembnega srčnožilnega obolenja se pojavi padec hemoglobina na < 8,5 g/dl; (2) pri bolniku s stabilnim srčnožilnim obolenjem ostaja vrednost hemoglobina na < 12 g/dl kljub štiritedenskemu zmanjšanemu odmerku.
English: At Week 48 of Pegasys treatment, a height or weight percentile decrease of more than 15 percentiles on the normative growth curves was observed in 6% of patients for height and 11% of patient for weight, whereas in the untreated group it was 2% of patients for height and 9% for weight.
Slovenian: V 48. tednu zdravljenja z zdravilom Pegasys so opazili zmanjšanje percentila višine ali telesne mase za 15 percentilov ali več glede na normativni krivulji rasti pri 6 % bolnikov za višino in 11 % bolnikov za telesno maso, medtem ko sta bila deleža v nezdravljeni skupini 2 % bolnikov za višino in 9 % za telesno maso.
English: All patients were followed for 24 weeks post-treatment.
Slovenian: Vse bolnike so spremljali 24 tednov po končanem zdravljenju.
English: Ribavirin number of tablets
Slovenian: Število tablet ribavirina
English: The results of study NV15942 provide the rationale for recommending treatment regimens based on genotype, baseline viral load and virological response at week 4 (see Tables 1, 14 and 15).
Slovenian: Rezultati študije NV15942 predstavljajo osnovo za priporočila za zdravljenje v odvisnosti od genotipa, virusnega bremena pred začetkom zdravljenja in virološkega odziva v 4. tednu (glejte preglednice 1, 14 in 15).
English: By HBV-DNA (IU/mL) decline from baseline to week 12
Slovenian: Glede na znižanje HBV-DNA (i.e./ml) od izhodišča do 12. tedna
English: The safety and efficacy of Pegasys and ribavirin treatment have not been established in patients with liver and other transplantations.
Slovenian: Varnosti in učinkovitosti zdravljenja z zdravilom Pegasys ter ribavirinom pri bolnikih s presajenimi jetri ali drugimi presadki niso proučevali.
English: Table 25: Sustained virological response in the NV17424 study Pegasys 180 mcg x BSA/1.73 m² + Ribavirin 15 mg/kg (N=55)*
Slovenian: Preglednica 25: Trajni virološki odziv v študiji NV17424 Zdravilo Pegasys 180 µg x TP/1,73 m² + ribavirin 15 mg/kg (n = 55)*
English: Patients who still have detectable levels of HCV-RNA despite an initial 24 weeks of therapy, should discontinue therapy, as it is unlikely they will be able to achieve a sustained virological response with continued therapy.
Slovenian: Bolniki, ki še imajo merljivo koncentracijo HCV-RNA kljub 24-tedenskemu zdravljenju, naj z zdravljenjem prekinejo, saj je malo verjetno, da bi z nadaljevanjem zdravljenja dosegli trajen virološki odziv.
English: Cases of pulmonary arterial hypertension (PAH) have been reported with interferon alfa products, notably in patients with risk factors for PAH (such as portal hypertension, HIV infection, cirrhosis).
Slovenian: Pri uporabi zdravil, ki vsebujejo interferon alfa, so poročali o primerih pljučne arterijske hipertenzije (PAH) zlasti pri bolnikih z dejavniki tveganja zanjo (to so na primer portalna hipertenzija, okužba z virusom HIV ali ciroza).
English: The frequencies observed (4.9%) in patients receiving Pegasys/ribavirin (NV15801) are similar to those observed with other interferons.
Slovenian: Pogostnost pri bolnikih, ki so prejemali zdravilo Pegasys in ribavirin (NV15801), je bila podobna kot pri zdravljenjih z drugimi interferoni (4,9 %).
English: ● Clean and disinfect the skin where the injection is to be made with a cleansing swab.
Slovenian: ● Z dezinfekcijsko krpico očistite in dezinficirajte kožo na mestu, kjer si boste dali injekcijo.
English: Peginterferon alfa-2a is found predominantly in the bloodstream and extracellular fluid as seen by the volume of distribution at steady-state (Vd) of 6 to 14 litres in humans after intravenous administration.
Slovenian: Peginterferon alfa-2a najdemo večinoma v krvnem obtoku in ekstracelularni tekočini, volumen porazdelitve v stanju dinamičnega ravnovesja (Vd) je od 6 do 14 litrov pri ljudeh po intravenskem dajanju.
English: Treatment should be initiated only by a physician experienced in the treatment of patients with hepatitis B or C.
Slovenian: 4.2 Odmerjanje in način uporabe Zdravljenje lahko začne le zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hepatitisom B ali C.
English: You must use an effective contraceptive during the time you are taking the treatment and for 4 months after stopping treatment.
Slovenian: Med zdravljenjem in 4 mesece po končanem zdravljenju morate uporabljati učinkovito kontracepcijo.
English: The absorption of Pegasys is sustained with peak serum concentrations reached 72 to 96 hours after dosing.
Slovenian: Po absorpciji zdravilo Pegasys doseže največje koncentracije v serumu v 72 do 96 urah po odmerku.
English: Dose adjustement in paediatric patients - dual therapy with Pegasys and ribavirin
Slovenian: Prilagajanje odmerkov pri pediatričnih bolnikih - dvojna terapija zdravila Pegasys in ribavirina
English: In clinical trials of 48 weeks treatment and 24 weeks follow-up, the safety profile for Pegasys in CHB was similar to that seen in CHC.
Slovenian: V kliničnih preskušanjih zdravljenja, ki je trajalo 48 tednov, in v obdobju sledenja bolnikov, ki je trajalo 24 tednov, je bil varnostni profil zdravila Pegasys pri bolnikih s CHB podoben kot pri bolnikih s CHC.
English: Pegasys treatment was associated with abnormal laboratory values: ALT increase, bilirubin increase, electrolyte disturbance (hypokalaemia, hypocalcaemia, hypophosphataemia), hyperglycaemia, hypoglycaemia and elevated triglycerides (see section 4.4.).
Slovenian: Zdravljenje z zdravilom Pegasys je bilo povezano s patološkimi laboratorijskimi vrednostmi: zvečane koncentracije ALT, zvišan bilirubin, motnje elektrolitov (hipokaliemija, hipokalciemija, hipofosfatemija), hiperglikemija, hipoglikemija in zvišani trigliceridi (glejte poglavje 4.4).
English: Reduce Pegasys to 135/90/45 micrograms
Slovenian: Zmanjšamo odmerek zdravila Pegasys na 135/90/45
English: Pegasys is contraindicated in neonates and young children up to 3 years old due to the excipient benzyl alcohol (see sections 4.3 and 4.4).
Slovenian: Zdravilo Pegasys je kontraindicirano pri novorojenčkih in mlajših otrocih, starih do 3 let, zaradi pomožne snovi benzilalkohol (glejte poglavji 4.3 in 4.4).
English: No response by week
Slovenian: Ni odziva do 12. tedna
English: 6) Place pre-filled pen on injection site 7) Give injection
Slovenian: 6) Napolnjeni injekcijski peresnik približajte mestu injiciranja 7) Dajte injekcijo
English: Study NV15801
Slovenian: Študija NV15801
English: Adverse events or laboratory abnormalities led to 5% of patients withdrawing from Pegasys treatment, while less than 1% of patients withdrew from lamivudine treatment for these reasons.
Slovenian: Neželeni dogodki ali laboratorijske nepravilnosti so vodili do prekinitve zdravljenja z zdravilom Pegasys pri 5 % bolnikov, zdravljenje z lamivudinom pa je zaradi enakih razlogov prekinil manj kot 1 % bolnikov.
English: Name and address of the manufacturer(s) of the biological active substance
Slovenian: Ime in naslov izdelovalca biološke zdravilne učinkovine
English: HCV patients with normal ALT
Slovenian: Bolniki s HCV z normalnimi vrednostmi ALT
English: Place pre-filled pen straight up on the skin fold at a right angle (90°) on the injection site.
Slovenian: Postavite peresnik navpično na kožno gubo pod pravim kotom (90°) na mesto injiciranja.
English: The solution is clear and colourless to light yellow.
Slovenian: Bistra in brezbarvna do rahlo rumena raztopina.
English: The following instructions explain how to use Pegasys single dose vials to inject yourself or your child.
Slovenian: Naslednja navodila opisujejo, kako lahko zdravilo Pegasys z injekcijsko brizgo injicirate sebi ali vašemu otroku.
English: What Pegasys looks like and contents of the pack
Slovenian: Izgled zdravila Pegasys in vsebina pakiranja
English: Please be sure to read the ribavirin package leaflet also.
Slovenian: Prosimo, preberite tudi navodilo za uporabo za ribavirin.
English: ● Insert the needle through the rubber top of the Pegasys vial (3).
Slovenian: ● Iglo potisnite skozi pokrov iz gume na viali zdravila Pegasys (3).
English: Pinch and hold a fold of skin at the injection site with your free hand, such that the needle-shield can rest on the skin-fold firmly and safely.
Slovenian: S prosto roko naredite kožno gubo na mestu injiciranja, tako da lahko ščitnik za iglo na njej počiva stabilno in varno.
English: This syndrome is a granulomatous inflammatory disorder affecting the eyes, auditory system, meninges, and skin.
Slovenian: Gre za granulomatozno vnetno bolezen, ki prizadane oči, slušni aparat, meninge in kožo.
English: The occurrence of anaemia (haemoglobin <10 g/dl) has been observed in up to 15% of CHC patients in clinical trials on the combined treatment of Pegasys with ribavirin.
Slovenian: Pojavnost anemije (hemoglobin < 10 g/dl) so opazili pri do 15 % bolnikov s CHC v kliničnih preskušanjih kombiniranega zdravljenja zdravila Pegasys in ribavirina.
English: It is recommended that Pegasys pre-filled syringes be used for children and adolescents, as they allow for dose adjustments.
Slovenian: Pri otrocih in mladostnikih je priporočljiva uporaba zdravila Pegasys v obliki napolnjenih injekcijskih brizg, saj omogočajo prilagoditev odmerka.
English: Only HIV-HCV co-infected patients were included in the study NR15961 (see Table 21).
Slovenian: V študijo NR15961 so bili vključeni le bolniki, okuženi s HIV in HCV (glejte preglednico 21).
English: Dose reduction to 90 micrograms is recommended if the platelet count is 25,000 to < 50,000 cells/mm3.
Slovenian: Zmanjšanje odmerka na 90 mikrogramov je priporočljivo, če je število trombocitov 25.000 do < 50.000 celic/mm3.
English: Table 12: Serological, virological and biochemical responses in chronic hepatitis B HBeAg positive Study WV16240
Slovenian: Preglednica 12: Serološki, virološki in biokemični odzivi pri CHB HBeAg pozitivni študija WV16240
English: When the increase in ALT levels is progressive and clinically significant, despite dose reduction, or is accompanied by increased direct bilirubin, therapy should be discontinued (see sections 4.2 and 4.8).
Slovenian: Če je kljub znižanju odmerka zvečanje koncentracij ALT progresivno ali klinično značilno ali če ga spremlja zvišan direktni bilirubin, moramo zdravljenje prekiniti (glejte poglavji 4.2 in 4.8).
English: Growth inhibition was observed in paediatric patients (see section 4.4).
Slovenian: Pri pediatričnih bolnikih so opazili zastoj rasti (glejte poglavje 4.4).
English: The SVRs reported in the treatment arms of this study were similar to the corresponding treatment arms from study NV15942.
Slovenian: Trajni virološki odziv, o katerem so poročali v skupinah bolnikov te študije, je bil podoben kot v primerljivih skupinah bolnikov študije NV15942.
English: All clinical trials recruited patients with CHB who had active viral replication measured by HBV DNA, elevated levels of ALT and a liver biopsy consistent with chronic hepatitis.
Slovenian: Vsi bolniki s CHB, ki so bili vključeni v klinična preskušanja, so imeli aktivno virusno replikacijo, izmerjeno s HBV DNA, zvišane vrednosti ALT in jetrno biopsijo v skladu s kroničnim hepatitisom.
English: Wash your hands carefully before handling any of the items.
Slovenian: Priprava Pazljivo si najprej operite roke.
English: While fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever, particularly serious infections (bacterial, viral, fungal) must be ruled out, especially in patients with neutropenia.
Slovenian: Čeprav je zvišana telesna temperatura lahko povezana z gripi podobnim sindromom, ki ga pogosto opisujejo med zdravljenjem z interferoni, moramo izključiti druge vzroke dolgotrajne zvišane telesne temperature, še posebno resne okužbe (bakterijske, virusne, glivične), zlasti pri bolnikih z nevtropenijo.
English: With both Pegasys monotherapy, and also the combined treatment with ribavirin, up to 2% of patients experienced increased ALT levels that led to dose modification or discontinuation of the treatment.
Slovenian: Pri samostojnem in kombiniranem zdravljenju zdravila Pegasys z ribavirinom so se pri do 2 % bolnikov pojavile zvečane koncentracije ALT, zaradi katerih so odmerek spremenili ali pa so zdravljenje prekinili.
English: Pegasys pharmacokinetics have been characterized in paediatric patients with CHB (YV25718), as well as in paediatric patients with CHC (NR16141), using population pharmacokinetics.
Slovenian: Farmakokinetiko zdravila Pegasys so ovrednotili z uporabo populacijske farmakokinetike pri pediatričnih bolnikih s CHB (YV25718) in pri pediatričnih bolnikih s CHC (NR16141).
English: Patients co-infected with HIV and receiving Highly Active Anti-Retroviral Therapy (HAART) may be at increased risk of developing lactic acidosis.
Slovenian: Pri bolnikih, ki so sočasno okuženi z virusom HIV in prejemajo visoko aktivno protiretrovirusno terapijo (HAART - Highly Active Anti-Retroviral Therapy), obstaja večje tveganje za nastanek laktacidoze.
English: Side effects with unknown frequency:
Slovenian: Neželeni učinki, katerih pogostnost ni znana:
English: <1 log10 decline
Slovenian: < 1 log10
English: Pegasys use is restricted to children and adolescents with chronic hepatitis C aged 5 years and above or children and adolescents with chronic hepatitis B aged 3 years and above.
Slovenian: Uporaba zdravila Pegasys je omejena na otroke in mladostnike s kroničnim hepatitisom C, stare 5 let ali več, in na otroke in mladostnike s kroničnim hepatitisom B, stare 3 leta ali več.
English: Caution should therefore be exercised when adding Pegasys and ribavirin to HAART therapy (see ribavirin SmPC).
Slovenian: Pri uvajanju zdravila Pegasys in ribavirina v HAART je zato potrebna previdnost (glejte SmPC za ribavirin).
English: Clean the area using the alcohol pad and put the pad aside to wipe the site again after injection, if necessary.
Slovenian: Očistite mesto z alkoholnim zložencem in ga odložite, če ga boste ponovno potrebovali po injiciranju.
English: Although limited, data indicated that shortening treatment to 24 weeks might be associated with a higher risk of relapse (see Table 16).
Slovenian: Čeprav so podatki omejeni, kažejo na to, da je skrajšanje zdravljenja na 24 tednov lahko povezano z večjim tveganjem za ponovitev bolezni (glejte preglednico 16).
English: A patient-level meta-analysis of 9 Pegasys clinical studies (n=1,423) in CHB HBeAg positive and HBeAg-negative patients demonstrated that HBsAg and HBV DNA levels at Week 12 of treatment, are predictive of final treatment outcome at Week 24 post-treatment in certain genotypes.
Slovenian: Metaanaliza 9 kliničnih študij zdravila Pegasys na ravni bolnikov (n = 1423) pri bolnikih s kroničnim hepatitisom B, ki so HBeAg pozitivni ali negativni, je pokazala, da ravni HBsAg in HBV DNA v 12. tednu zdravljenja za določene genotipe napovedujejo končni izid zdravljenja v 24. tednu po končanem zdravljenju.
English: In a clinical trial (YV25718) with 111 paediatric patients (3 to 17 years of age) treated with Pegasys for 48 weeks, the safety profile was consistent with that seen in adults with CHB and in paediatric patients with CHC.
Slovenian: V kliničnem preskušanju (YV25718) s 111 pediatričnimi bolniki (starimi od 3 do 17 let), ki so jih zdravili z zdravilom Pegasys 48 tednov, je bil varnostni profil skladen s tistim pri odraslih s CHB in pri pediatričnih bolnikih s CHC.
English: For a few subjects who were more than 15 percentiles below their baseline height curve at 2 years post-treatment, they either returned to baseline comparable height percentiles at 6 years post-treatment or a non-treatment related causative factor has been identified.
Slovenian: Nekateri preizkušanci, ki so dve leti po zdravljenju ostali več kot 15 percentilov pod svojo izhodiščno rastno krivuljo z začetka zdravljenja, so se šest let po zdravljenju vrnili k percentilom višine, ki so primerljivi z začetkom zdravljenja, ali pa je bil ugotovljen z zdravljenjem nepovezan vzročni dejavnik.
English: The AUC was slightly increased (1663 vs. 1295 ng·h/ml) but peak concentrations (9.1 vs. 10.3 ng/ml) were similar in subjects older than 62 years.
Slovenian: AUC je bila pri mlajših malo večja (1663 proti 1295 ng·h/ml), največje koncentracije pa so bile podobne kot pri bolnikih, starejših od 62 let (9,1 pri mlajših in 10,3 ng/ml pri starejših).
English: After the injection: Wipe the injection site with the alcohol pad, if necessary.
Slovenian: Obrišite mesto injiciranja z alkoholnim zložencem, če je potrebno.
English: The data indicated that shortening treatment to 16 weeks is associated with a higher risk of relapse (see Table 18).
Slovenian: Podatki kažejo, da je skrajšanje zdravljenja na 16 tednov povezano z večjim tveganjem za ponovitev bolezni (glejte preglednico 18).
English: Breathing disorders: Interstitial pneumonia (inflammation of the lungs including fatal outcome), blood clots in the lung
Slovenian: Bolezni dihal: intersticijska pljučnica (vnetje pljuč, vključno s smrtnim izidom), krvni strdki v pljučih.
English: ● use if medicine is cloudy, hazy, discoloured or has particles in it.
Slovenian: • uporabljajte peresnika, če je zdravilo motno, nejasno, obarvano ali vsebuje delce;
English: Interferon alfa-2a is conjugated with bis-[monomethoxy polyethylene glycol] at a degree of substitution of one mole of polymer/mole of protein.
Slovenian: Interferon alfa-2a je konjugiran z molekulo bis-[monometoksipolietilenglikol] pri stopnji substitucije en mol polimera na mol proteina.
English: The recommended duration of Pegasys monotherapy is 48 weeks.
Slovenian: Priporočeno trajanje samostojnega zdravljenja z zdravilom Pegasys je 48 tednov.
English: Fever/infections
Slovenian: Zvišana telesna temperatura/okužbe
English: Puh/Tel: +358 (0) 10 554 500
Slovenian: Roche Oy Puh/Tel: +358 (0) 10 554 500
English: ● if the patient is a child who has ever had serious psychiatric conditions such as severe depression or thoughts of committing suicide.
Slovenian: • je bolnik otrok, ki se je kadar koli nahajal v hudem psihičnem stanju, kot je huda depresija ali misli o samomoru,
English: 2) Allow the pre-filled pen to adjust to room temperature
Slovenian: 2) Pustite, da se napolnjeni injekcijski peresnik ogreje na sobno temperaturo
English: Patients infected with HCV genotypes other than genotype 1 should receive 800 mg daily of ribavirin.
Slovenian: Bolnikom, ki so okuženi z drugimi HCV genotipi, razen genotipa 1, dajemo 800 mg ribavirina na dan.
English: Patients with substance use/abuse: HCV infected patients having a co-occurring substance use disorder (alcohol, cannabis, etc) are at an increased risk of developing psychiatric disorders or exacerbation of already existing psychiatric disorders when treated with alfa interferon.
Slovenian: Bolniki z anamnezo uporabe/zlorabe psihoaktivnih substanc: Pri bolnikih, ki so okuženi z virusom hepatitisa C in imajo sočasno anamnezo zlorabe psihoaktivnih substanc (alkohol, kanabis, ipd.), obstaja povečano tveganje za nastanek novih ali poslabšanje že obstoječih psihiatričnih motenj, če jih zdravimo z interferonom alfa.
English: In these patients, tolerability to combination therapy and additional prognostic factors such as degree of fibrosis should be taken into account when deciding on treatment duration.
Slovenian: Pri teh bolnikih je pri odločanju o trajanju zdravljenja treba razmisliti o prenašanju kombiniranega zdravljenja in dodatnih prognostičnih dejavnikih, kot je stopnja fibroze.
English: b Patients who achieved viral suppression at week 12 but were missing HCV RNA results at the end of follow-up were considered to be non-responders.
Slovenian: Bolnike, ki so dosegli virusno supresijo v 12. tednu, a podatkov o njihovi koncentraciji HCV RNA na koncu spremljanja ni bilo, so smatrali za neodzivne.
English: There was no difference in response rate between these patients and those without advanced fibrosis or cirrhosis.
Slovenian: Med temi bolniki in bolniki brez napredovale fibroze ali ciroze ni bilo razlik v deležu odziva.
English: The most frequently reported adverse reactions with Pegasys 180 micrograms were mostly mild to moderate in severity and were manageable without the need for modification of doses or discontinuation of therapy.
Slovenian: Najpogosteje opisani neželeni učinki pri odmerku 180 mikrogramov zdravila Pegasys so bili večinoma blagi do srednje hudi in so jih lahko odpravili brez prilagajanja odmerka ali prekinitve zdravljenja.
English: Peripheral ischaemia
Slovenian: vaskulitis periferna ishemija
English: MONITOR Assay (limit of detection 200 copies/ml).
Slovenian: (meja detekcije 200 kopij/ml).
English: There are no data in paediatric patients coinfected with HCV/HIV or with renal impairment.
Slovenian: Podatkov o pediatričnih bolnikih, sočasno okuženih z HCV in HIV ali z okvaro ledvic, ni na voljo.
English: ● if you develop symptoms of Vogt-Koyanagi-Harada syndrome; combination of complaints of neck stiffness, headache, loss of colour in skin or hair, eye disorders (such as blurred vision), and/or hearing abnormality (such as ringing in the ears).
Slovenian: • če se pri vas pojavi Vogt-Koyanagi-Haradov sindrom ali imate kombinacijo težav, ki vključujejo trd vrat, glavobol, razbarvanje kože ali las, težave z očmi (kot je moten vid) in/ali motnje sluha (kot je zvonjenje v ušesih).
English: Blood disorders: Aplastic anaemia (failure of the bone marrow to produce red blood cells, white blood cells and platelets)
Slovenian: Bolezni krvi: aplastična anemija (kostni mozeg ni sposoben tvoriti rdečih krvnih celic, belih krvnih celic in trombocitov).